AI News Sentiment & Analysis
Collegium Pharmaceutical, Inc. (COLL) — AI News Sentiment & Analysis
3 recent AI analyses of Collegium Pharmaceutical, Inc. (COLL) stock news and press releases, with sentiment and confidence scoring updated continuously.
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
BullishEarnings ReleaseStrong Q1 2026 earnings report, reaffirmation of current business guidance, and positive progress towards closing the AZSTARYS acquisition. (Timing: Immediate (Q1 results), Q2 2026 (acquisition close).)May 7, 2026Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
BearishCollegium's definitive agreement to acquire AZSTARYS for $650 million cash, with potential milestones up to $135 million, alongside the market's negative response to the deal's financing structure. (Timing: The transaction is expected to close in the second quarter of 2026, with the financial impacts and integration challenges becoming clearer from the second half of 2026.)Mar 19, 2026Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
BullishCollegium Pharmaceutical announced a partnership with Paris Hilton to promote ADHD awareness. This partnership could enhance the company's visibility and potentially drive demand for its ADHD treatment, JORNAY PM. The campaign aims to normalize conversations around ADHD, which may unlock value for the company.Mar 3, 2026
Want the full picture?
These are AI-read press-release catalysts. Sign up to see complete investment theses, valuation rationales, entry/exit strategies, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Collegium Pharmaceutical, Inc. (COLL) bullish or bearish right now?
AI Sentiment on COLL: 2 Bullish, 1 Bearish.
What was the latest AI analysis for Collegium Pharmaceutical, Inc. (COLL)?
The latest analysis was published on 5/7/2026 with the headline: "Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress".
How does Bekodia analyze Collegium Pharmaceutical, Inc. (COLL) stock?
Bekodia uses advanced AI models to process Collegium Pharmaceutical, Inc. (COLL) press releases and news in real-time, extracting sentiment, confidence scores, and key investment catalysts while filtering out market noise.